Program
Fluconazole
Also written as “fluconazole”, “Fluconazole 400 mg” and “Diflucan®”.
Its studies are mostly in Meningitis, Cryptococcal · Candidiasis · Candidiasis, Oral · Candidemia · Lymphoma, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 260 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Merck | 30 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| AstraZeneca | 20 open or running | phase 1since Mar 20, 2014 | Mar 20, 2014 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Jan 13, 2012 | Jan 13, 2012 | none ahead |
| Bayer | 10 open or running | phase 1since Apr 17, 2019 | Apr 17, 2019 | none ahead |
| Johnson & Johnson | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Pharmtechnology | 10 open or running | phase 1since Jul 26, 2019 | Jul 26, 2019 | none ahead |
| Sutphin Drugs | 10 open or running | early phase 1since Jul 31, 2020 | Jul 31, 2020 | none ahead |
Also a collaborator on its studies: altasciences-company-inc, impact-biomedicines-inc-a-wholly-owned-subsidiary-of-celgene and vicuron-pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 22 studies since Nov 2, 1999.
- Mar 11, 2003Phase 3 study in CandidiasisPfizer · NCT00056368 · 256 enrolled · United States
- Mar 25, 2008Phase 3 study in Tinea CapitisPfizer · NCT00645242 · 185 enrolled · United States, Puerto Rico
- May 29, 2008Phase 3 study in Candidiasis, InvasivePfizer · NCT00689338 · 216 enrolled · Austria, Belgium, Canada and more
- Dec 18, 2008Phase 3 study in LeukopeniaMerck · NCT00811928 · 252 enrolled
- Aug 3, 2010Phase 3 study in CandidemiaPfizer · NCT01176058 · 17 enrolled · China
- Jan 13, 2012Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01511770, NCT01511757
- Jan 28, 2013Phase 3 study in Candidiasis, VulvovaginalPfizer · NCT01806623 · 157 enrolled · Japan
- Mar 20, 2014AstraZeneca's first study: phase 1 study in Solid TumoursNew to AstraZenecaAstraZeneca · NCT02093728 · 26 enrolled · United States
- Aug 20, 2014Phase 1 study in NeoplasmsPfizer · NCT02222922 · 138 enrolled · United States, Spain
- Aug 3, 2018Phase 1 study in BioequivalencePfizer · NCT03621072 · 36 enrolled · China
- Apr 17, 2019Bayer's first study: phase 1 study in Pharmacology, ClinicalNew to BayerBayer · NCT03929861 · 26 enrolled · Germany
- Jul 26, 2019Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT04038008 · 26 enrolled · Canada
- Jul 31, 2020Sutphin Drugs's first study: early phase 1 study in CandidiasisNew to Sutphin DrugsSutphin Drugs · NCT04502277 · 200 enrolled · United States, India
- Nov 17, 2021Phase 1 study in Healthy VolunteersAstraZeneca · NCT05140096 · 30 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05140096Healthy Volunteers · United States | 1 | Completed | AstraZeneca | Apr 15, 2020 | 30 |
| NCT04502277Candidiasis · United States, India | Early 1 | UNKNOWN | Sutphin Drugs | Dec 31, 2020 | 200 |
| NCT04038008Bioequivalence · Canada | 1 | Completed | Pharmtechnology | Sep 17, 2019 | 26 |
| NCT03929861Pharmacology, Clinical · Germany | 1 | Completed | Bayer | Sep 10, 2012 | 26 |
| NCT03621072Bioequivalence · China | 1 | Completed | Pfizer | Jul 20, 2019 | 36 |
| NCT02222922Neoplasms · United States, Spain | 1 | Completed | Pfizer | Nov 5, 2019 | 138 |
| NCT02093728Solid Tumours · United States | 1 | Completed | AstraZeneca | Jun 2014 | 26 |
| NCT01806623Candidiasis, Vulvovaginal · Japan | 3 | Completed | Pfizer | Nov 22, 2013 | 157 |
| NCT01511770Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Aug 2002 | 17 |
| NCT01511757Healthy · Canada | 1 | Completed | Dr. Reddy's Laboratories | Jun 2002 | 15 |
| NCT01176058Candidemia · China | 3 | Terminated | Pfizer | Nov 2011 | 17 |
| NCT00811928Leukopenia | 3 | Completed | Merck | May 2010 | 252 |
| NCT00689338Candidiasis, Invasive · Austria, Belgium, Canada and more | 3 | Completed | Pfizer | May 2010 | 216 |
| NCT00645242Tinea Capitis · United States, Puerto Rico | 3 | Completed | Pfizer | 185 | |
| NCT00056368Candidiasis · United States | 3 | Completed | Pfizer | 256 | |
| NCT00002446Candidiasis, Oral · United States, Barbados | 3 | Completed | Merck | 300 | |
| NCT00002399Candidiasis, Oral · United States, Argentina, Belgium and more | 2 | Completed | Merck | 500 | |
| NCT00002339Candidiasis · United States | 3 | Completed | Pfizer | 100 | |
| NCT00002325Mycoses · United States | – | Completed | Pfizer | ||
| NCT00002306Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002305Meningitis, Cryptococcal · United States, Canada | – | Completed | Pfizer | ||
| NCT00002304Candidiasis · United States, Canada | – | Completed | Pfizer | ||
| NCT00002294Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002282Candidiasis, Oral · United States | – | Completed | Pfizer | ||
| NCT00002277Mycoses · United States | 3 | Completed | Pfizer | ||
| NCT00002132Candidiasis · United States | – | Completed | Johnson & Johnson | ||
| NCT00002113Meningitis, Cryptococcal · United States | – | Completed | Pfizer | 64 | |
| NCT00002112Candidiasis, Oral · United States | – | Completed | Pfizer | ||
| NCT00002077Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002076Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002075Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002074Meningitis, Cryptococcal · United States, Canada | – | Completed | Pfizer | ||
| NCT00002068Meningitis, Cryptococcal · United States, Canada | – | Completed | Pfizer | ||
| NCT00002040Meningitis, Cryptococcal · United States | – | Completed | Pfizer | ||
| NCT00002038Candidiasis · United States | – | Completed | Pfizer | ||
| NCT00002010Meningitis · United States | – | Completed | Pfizer | ||
| NCT00001017Meningitis, Cryptococcal · United States | 3 | Completed | Pfizer | Jul 1991 | 330 |
How it is read
Names in the registry
- “Fluconazole”, 36 entries
- “fluconazole”, 5 entries
- “Fluconazole 400 mg”, 1 entry
- “Diflucan®”, 1 entry
- “Fluconazole 150mg Capsule Localized Originator”, 1 entry
Conditions, from the studies’ own filings
- Meningitis, Cryptococcal, 11 studies
- Candidiasis, 5 studies
- Candidiasis, Oral, 4 studies
- Candidemia, 3 studies
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.